Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423954 · ClinicalTrials.gov registry record · Phase 1
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02423954: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02423954 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02423954, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Determine Phase 2 dose of study drug
Interventions
- DRUG Irinotecan
- DRUG nivolumab
- DRUG Temsirolimus
- DRUG Irinotecan + capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02423954
The ClinicalTrials.gov registry entry for NCT02423954 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Irinotecan is the first listed.
NCT02423954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02423954 about?
NCT02423954 is a clinical study titled "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)". Determine Phase 2 dose of study drug
What is the current status of trial NCT02423954?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-04. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT02423954?
The interventions under investigation include: Irinotecan (DRUG), nivolumab (DRUG), Temsirolimus (DRUG), Irinotecan + capecitabine (DRUG).
Who is sponsoring clinical trial NCT02423954?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.